Abstract 367P
Background
Prostate cancer is a prevalent and impactful disease affecting men’s health, with treatment options often compromising quality of life. Enzalutamide, an androgen receptor inhibitor, has emerged as a promising therapeutic option for prostate cancer. This study aims to assess the effects of enzalutamide on health-related quality of life (HRQoL) in men with prostate cancer, offering valuable insights into the treatment outcomes and aiding clinical decision-making.
Methods
Studies were collected from several databases, such as PubMed, Google Scholar, and PubMed Central (PMC), using MeSH keywords “quality of life” AND “prostate cancer” AND “enzalutamide” from 9th till 16th July 2024 by two independent researchers. Randomized controlled trials which include >18 years old patients with prostate cancer. Studies on animals, case reports, systematic reviews/meta-analysis, and patients with disease progression with previously received ADT were excluded. Quality of studies included were all assessed using Risk of Bias 2.0 tools. Our primary outcome in this study was health-related quality of life (HRQoL).
Results
Seven out of fourteen eligible ones were included, involving 8,307 patients with prostate cancer. Six out of the seven studies had shown enzalutamide to produce better outcome in increasing the HRQoL compared to the placebo group while one study showed no significant differences between the two groups. Overall, enzalutamide showed a better health-related quality of life with fewer adverse effects in comparison to placebo. Five studies had a rigorous quality based on RoB 2.0, while two studies had a fair quality.
Conclusions
In conclusion, enzalutamide was superior than placebo in increasing health-related quality of life in patients with prostate cancer. Thus, we still need further studies to clarify our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.